| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -151,199 | -97,347 |
| Amortization of right-of-use assets | 3,994 | 2,620 |
| Depreciation of property and equipment | 2,596 | 1,740 |
| Share-based compensation expense | 17,621 | 11,149 |
| Accounts receivable | 8,578 | 195 |
| Prepaid expenses | -2,891 | -2,844 |
| Other assets | -4,766 | 81 |
| Accounts payable | -1,717 | -1,776 |
| Accrued expenses and other current liabilities | -4,594 | -8,055 |
| Deferred revenue | -13,865 | -16,257 |
| Operating lease liabilities | -5,632 | -3,693 |
| Net cash used in operating activities | -153,717 | -109,051 |
| Purchases of property and equipment | 719 | 471 |
| Net cash used in investing activities | -719 | -471 |
| Proceeds from the issuance of ordinary shares, net of offering costs | 0 | - |
| Proceeds from the issuance of pre-funded warrants, net of offering costs | 0 | - |
| Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs | 42,573 | 12,361 |
| Proceeds from the exercise of share options | 5,086 | 3,045 |
| Proceeds from the espp | 881 | 442 |
| Net cash provided by financing activities | 48,540 | 15,848 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | 72 | 101 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -105,824 | -93,573 |
| Cash and cash equivalents at beginning of period | 305,838 | - |
| Cash and cash equivalents at end of period | 200,014 | - |
Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE)